Wyss Institute

Wyss Institute’s AminoX project receives funding from Northpond Labs to accelerate innovation in protein-based therapeutics

Retrieved on: 
Monday, April 8, 2024
Molecule, Research, Innovation, Patient, DNA, Wyss Institute, Engineering, Protein, Laboratory, Organic acid, Harvard University, CRISPR, Drug development, Wyss, Biological engineering, Therapy, Genetic code, FDA, Antiandrogen, Vocabulary, Fine chemical

This is the fourth Wyss project selected by Northpond Labs for additional funding.

Key Points: 
  • This is the fourth Wyss project selected by Northpond Labs for additional funding.
  • The Laboratory has previously funded the Wyss’ eRNA (now being commercialized by EnPlusOne Biosciences ), SomaCode , and Lab-on-a-Molecule projects.
  • “The AminoX platform has the potential to transform our ability to develop differentiated protein-based therapeutics by significantly expanding the vocabulary of building blocks that can be incorporated into biologics at high throughput.
  • We are thrilled that the AminoX team’s journey to the market will be accelerated by this support,” said Angelika Fretzen, Ph.D., M.B.A., the Wyss Institute’s Technology Translation Director & Chief Operating Officer.

Molecular Robotics Market Share Analysis, Industry Trends & Statistics and 10 Year Growth Forecasts 2019-2029

Retrieved on: 
Thursday, March 21, 2024
Diagnosis, University, Qiagen, Breast cancer, PerkinElmer, Lung cancer, Medical device, Research, Government, Burn, Drug discovery, Health, Pressure, Growth, Prevalence, Organization, Learning, Figure, Prostate cancer, The BMJ, Tufts University, Incidence, Thermo Fisher Scientific, COVID-19, Danaher Corporation, Conditional sentence, American Cancer Society, RNA, DNA, Female, Robotics, Cancer, Software, Wyss Institute, Laboratory, Woman, Regenerative medicine, Harvard University, Drug development, Xenobot, Medical journal, Pharmaceutical industry

DUBLIN, March 21, 2024 /PRNewswire/ -- The "Molecular Robotics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 21, 2024 /PRNewswire/ -- The "Molecular Robotics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to ResearchAndMarkets.com's offering.
  • The molecular robotics market is expected to witness a CAGR of 18% over the forecast period.
  • Active participation of universities in drug research and molecular robotics is also supporting the growth of the studied market.
  • Most of the players focus on bringing technologically advanced products into the market to acquire the maximum market share.

EnPlusOne Biosciences to Address Advances in the Enzymatic Synthesis of RNA at the 11th Annual Oligo Networking Conference

Retrieved on: 
Monday, March 4, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Innovation, Enzyme, Doctor of Philosophy, MIT, Harvard University, Conference, Outline of health sciences, Wyss, RNA, George Church, Engineering, Oligonucleotide, Harvard Medical School, Wyss Institute, Fine chemical

EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that Dan Ahlstedt, COO, will be presenting the company’s ezRNA™ platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage (UK) campus on March 5, 2024.

Key Points: 
  • EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that Dan Ahlstedt, COO, will be presenting the company’s ezRNA™ platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage (UK) campus on March 5, 2024.
  • The two-day event will feature speakers from companies across life sciences discussing opportunities and challenges associated with the use of oligonucleotides in R&D and manufacturing by biopharmaceutical companies.
  • Mr. Ahlstedt’s presentation will highlight recent technical developments, and upcoming milestones, on the company’s proprietary enzymatic RNA oligonucleotide synthesis technology, as part of the Innovation in Manufacturing session at the event.
  • This community, from the beginning, has been supportive of our mission to deliver sustainable RNA at scale.

Empress Announces Formation of World Leading Scientific Advisory Board

Retrieved on: 
Tuesday, January 23, 2024
Software, Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Other Science, Health, Probability, Microbiome, Emperor, Harvard Medical School, National academy, Computational biology, Genetic engineering, Inflammatory bowel disease, University, Infection, Biological engineering, Therapy, Synthetic biology, DNA, Harvard University, Biostatistics, Biomedical engineering, MIT, Disease, NIH, Science Publishing Group, MacArthur Fellows Program, Metabolism, Wyss Institute, Entrepreneurship, Artificial intelligence, Cell growth, Distinguishing, Immunology, SAB, Dysbiosis, Microbiota, Biology, Dana–Farber Cancer Institute, Huntsman Cancer Institute, Mass spectrometry, Princeton University, Genomics, Public health, Protein, Diabetes, Pharmaceutical industry

Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced the formation of the Empress Scientific Advisory Board (SAB) with leading experts in synthetic biology, computational biology, genetics, chemistry, and metabolism and disease.

Key Points: 
  • Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced the formation of the Empress Scientific Advisory Board (SAB) with leading experts in synthetic biology, computational biology, genetics, chemistry, and metabolism and disease.
  • The SAB will work closely with the leadership at Empress Therapeutics to advance the company’s Chemilogics™ platform and pipeline of drug leads.
  • “We are honored to have these extraordinary scientific leaders join Empress in its mission to generate safe, effective medicines faster and more predictably,” said Jason Park, Ph.D., Co-Founder and CEO of Empress Therapeutics.
  • “Our Scientific Advisory Board provides invaluable expertise across multiple aspects of our Chemilogics™ platform, which uses AI to discover therapeutic chemistry encoded in genetic data.

Global 3D Printed Wearables Market Analysis Report 2023-2030: Innovative Hybrid 3D Printing Technology Promises Precision and Cost Efficiency - ResearchAndMarkets.com

Retrieved on: 
Friday, January 12, 2024
Technology, Consumer Electronics, Biotechnology, R&D, 3D, COVID-19, Wyss Institute, Harvard University, USD, Hospital, Growth, Video game

The "Global 3D Printed Wearables Market Size, Share & Trends Analysis Report by Product Type (Prosthetics, Orthopedic Implants), End-use (Hospital, Pharma & Biotech Companies), Region, and Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global 3D Printed Wearables Market Size, Share & Trends Analysis Report by Product Type (Prosthetics, Orthopedic Implants), End-use (Hospital, Pharma & Biotech Companies), Region, and Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global 3D printed wearables market size is expected to reach USD 6.67 billion by 2030, registering a CAGR of 8.0%
    3D printed wearable technology has witnessed high adoption in the healthcare industry.
  • Due to numerous technological innovations in the sector, the market is expected to witness significant growth over the forecast period.
  • In the first quarter of 2020, the COVID-19 outbreak disrupted the global supply chain of raw materials and manufacturing parts of 3D printing products.

Integrated Biosciences Announces Nature Publication Identifying New Class of Antibiotics Discovered Via Company’s AI-Powered Platform

Retrieved on: 
Wednesday, December 20, 2023
Research, Technology, Infectious Diseases, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, MRSA, Broad Institute, Wyss Institute, Drug discovery, Multimedia, Biology, Cell Systems, Deep learning, MIT, Biomedical engineering, Ageing, Inflammation, Cancer, AI, Leibniz Association, Notifiable disease, Harvard University, Machine learning, Toxicity, Nature, Intelligence, Medicine, Therapy, Fibrosis, Synthetic biology, Pharmaceutical industry

This discovery represents one of the first new classes of antibiotics in the past 60 years and is the first discovered leveraging an AI-powered platform built around explainable deep learning.

Key Points: 
  • This discovery represents one of the first new classes of antibiotics in the past 60 years and is the first discovered leveraging an AI-powered platform built around explainable deep learning.
  • Researchers at Integrated Biosciences have discovered the first-ever class of antibiotics identified using a new and explainable artificial intelligence.
  • In their study, the researchers virtually screened more than 12 million candidate compounds to identify this new class of antibiotics.
  • The publication, “Discovery of a structural class of antibiotics with explainable deep learning,” can be accessed on the Nature website at: https://www.nature.com/articles/s41586-023-06887-8 .

The NemetzGroup Announces Promotion of Marnie Hoolahan to President

Retrieved on: 
Tuesday, December 5, 2023
Health, Technology, Software, Networks, Internet, Pharmaceutical, Genzyme, The, HBA, Patient, Bristol Myers Squibb, Nemetz, Marketing, Wyss Institute, Health care, Wes Hoolahan, Babson College, Pleasure, Renewable energy, Management, Science

The NemetzGroup LLC today announced the promotion of Marnie Hoolahan to the role of president.

Key Points: 
  • The NemetzGroup LLC today announced the promotion of Marnie Hoolahan to the role of president.
  • “Her contributions have been integral to our team's exceptional reputation in the biopharma industry.”
    As president of The NemetzGroup, Hoolahan will assume additional responsibility for the firm’s strategic vision, financial growth, partnerships, and business operations.
  • “I am thrilled to assume this role at such an important time in our industry,” said Marnie Hoolahan, president of The NemetzGroup.
  • Working with our team can make all the difference in a company’s success.”
    Prior to joining The NemetzGroup, Hoolahan held various leadership roles at Genzyme Corporation, GelTex, and Bristol-Myers Squibb.

Spear Bio, developer of the next-generation ultrasensitive immunodiagnostics and proteomics platform, completes raise of tens of millions of US dollars with oversubscribed Seed Prime

Retrieved on: 
Wednesday, November 29, 2023
Microfluidics, DBS, Immunity, Research, DNA, Conditional sentence, Proteomics, Investment, Protein, Reproductive success, Disease, CDH, Patient, Multimedia, Neurology, Laboratory, SPEAR, Harvard University, Infection, COVID-19, Workflow, Ultra, Biomarker, Real-time, Wyss Institute, ELISA, Partnership, CDH Investments, Pharmaceutical industry, Medical imaging, Hunting

The oversubscribed round was led by CDH Investments, with additional investments from earlier investors such as Maverick Ventures and YongHua Capital.

Key Points: 
  • The oversubscribed round was led by CDH Investments, with additional investments from earlier investors such as Maverick Ventures and YongHua Capital.
  • Spear Bio was co-founded in March 2021 as a spin-off from Harvard University's Wyss Institute by Professor Peng Yin and Dr. Feng Xuan.
  • The company is developing the next generation ultrasensitive immunodiagnostics and proteomics platform based on a breakthrough technology its founders developed and licensed from Harvard University: the Successive Proximity Extension Amplification Reaction, or SPEAR.
  • Spear Bio is now focused on bringing to market ultrasensitive immunoassays for areas such as neurology, immunology, and oncology.

First Mice Engineered to Survive COVID-19 Like Young, Healthy Humans

Retrieved on: 
Wednesday, November 1, 2023
Wyss Institute, Neoplasm, ACE, ACE2, National Institutes of Health, Adenine, Opentrons, CDI, TP53, Obesity, Biochemistry, Human, DNAS, CRISPR, Genetics, G.H. Raisoni Department of Microbiology and Biotechnology, NYU Langone Health, Diabetes, Q-system (genetics), Doctor of Philosophy, Infection, Genetic code, Fungus, Cell, Wyss Institute for Biologically Inspired Engineering, Research, NYU, Mouse, Sol, Genome, COVID-19, Cancer, Guanine, New York University Grossman School of Medicine, Gene, Pharmacology, Cytosine, Patient, Bangladesh Technical Education Board, Mutation, AG, DNA, Vaccine, Pathology, Nature

NEW YORK, Nov. 1, 2023 /PRNewswire/ -- Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.

Key Points: 
  • NEW YORK, Nov. 1, 2023 /PRNewswire/ -- Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.
  • The mice with this genetic change developed symptoms similar to young humans infected with the virus causing COVID-19, instead of dying upon infection as had occurred with prior mouse models.
  • "This has been a major missing piece in efforts to develop new drugs against this virus."
  • Boeke also receives consulting fees and royalties from OpenTrons, and holds equity in the company.

Foresight Institute Announces 2023 Feynman Prize Winners

Retrieved on: 
Sunday, October 29, 2023
Wyss Institute, Foresight Institute, MacArthur, MIT, Nanotechnology, Collins, Therapy, Life, European Research Council, CRISPR, Broad Institute, Doctor of Philosophy, Research, Internet, Wyss Institute for Biologically Inspired Engineering, Multimedia, Yale University, American Physical Society, Fairy, Feynman Prize in Nanotechnology, University of Luxembourg, Machine learning, Physics, Nanostructure, Teaching, Nobel Prize in Chemistry, University, Nobel Prize, Van der Waals, Synthetic biology, Harvard University, Château, SAN, DNA, Creative industries, Pharmaceutical industry, Auction, Chemistry

SAN FRANCISCO, Oct. 29, 2023 /PRNewswire-PRWeb/ -- Established in 1986, Foresight Institute is a pioneering non-profit organization dedicated to the advancement of molecular manufacturing and transformative technologies. Navigating scientific areas often seen as too ambitious for traditional institutions, Foresight Institute is committed to shaping the long-term future of life through these technologies. Awarded since 1993, Foresight Institute's Feynman Prizes celebrate both established and emerging talents in the field of nanotechnology, embodying their vision of steering transformative technologies to benefit humanity.

Key Points: 
  • SAN FRANCISCO, Oct. 29, 2023 /PRNewswire-PRWeb/ -- Established in 1986, Foresight Institute is a pioneering non-profit organization dedicated to the advancement of molecular manufacturing and transformative technologies.
  • Navigating scientific areas often seen as too ambitious for traditional institutions, Foresight Institute is committed to shaping the long-term future of life through these technologies.
  • Awarded since 1993, Foresight Institute's Feynman Prizes celebrate both established and emerging talents in the field of nanotechnology, embodying their vision of steering transformative technologies to benefit humanity.
  • Foresight Institute also bestows the Distinguished Student Award, spotlighting an upcoming individual for their exceptional work in advancing nanotechnology development and understanding.